title: A single local application of recombinant human basic fibroblast growth factor accelerates initial angiogenesis during wound healing in rabbit ear chamber.
abstract: Local angiogenic therapy with recombinant human basic fibroblast growth factor (rhbFGF) has been used to promote wound healing. To obtain useful information for the development of optimal angiogenic therapy, we chronologically evaluated the effects of a single local application of rhbFGF on angiogenesis in a rabbit ear chamber model of wound healing by observing the subcutaneous vessel bed intravitally. New vessel formation during wound healing was macroscopically and microscopically evaluated for 5 wk. Each rabbit ear chamber received a single dose of 6 microg rhbFGF (treatment B1: n = 13), 18 microg rhbFGF (treatment B2: n = 16), or physiological saline as control (n = 13). At 1 wk the newly vascularized area was significantly larger in groups B1 and B2 than in control. At 2 wk, the vascularized areas in groups B1, B2, and control were similar. At 5 wk, the percentage of rabbits with complete vascularization was significantly larger in group B1 than in control. Capillary density at 5 wk was similar among the three groups. These results suggest that locally applied rhbFGF accelerated angiogenesis during early wound healing in rabbits; however, this effect was transient and no increase in capillary density occurred at the completion of vascularization.
authors.affiliation: Departments of *Anesthesiology and †Cardiovascular Surgery, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: Makiko
authors.initials: M
authors.lastname: Komori
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Tomizawa
authors.forename: Katsumi
authors.initials: K
authors.lastname: Takada
authors.forename: Makoto
authors.initials: M
authors.lastname: Ozaki
mesh_terms: D000287:Administration, Topical; D000818:Animals; D004423:Ear / Q000098:blood supply; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage*; D008297:Male; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D011817:Rabbits; D011994:Recombinant Proteins / Q000008:administration & dosage; D013045:Species Specificity; D014945:Wound Healing / Q000502:physiology*
chemical_list: D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2
references.citation: Risau W. Mechanisms of angiogenesis. Nature 1997;386:671–4.
references.citation: Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999;103:1231–6.
references.citation: Folkman J, Klagsburn M. Angiogenic factors. Science 1987;235:442–7.
references.citation: Gospodarowicz D. Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature 1974;249:123–7.
references.citation: Schumacher B, Pecher P, von Specht BU, et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998;97:645–50.
references.citation: Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788–93.
references.citation: Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002;359:2053–8.
references.citation: Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus. Circulation 2000;102:e73–86.
references.citation: Lathi KG, Vale PR, Losordo DW, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results. Anesth Analg 2001;92:19–25.
references.citation: Asano M, Yoshida K, Tatai K. On in vivo observation of the behavior of microcirculation by the rabbit ear chamber technique [in Japanese]. Seitai-no-kagaku 1962;13:285–94.
references.citation: Tomizawa Y, Suzuki Y, Miyama A, et al. Macroscopic sequential pictures of angiogenesis in a rabbit ear chamber. J Invest Surg 2002;15:269–74.
references.citation: Fu X, Shen Z, Chen Y, et al. Randomised placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns. Lancet 1998;352:1661–4.
references.citation: Sakakibara Y, Nishimura K, Tambara K, et al. Prevascularization with gelatin microspheres containing basic fibroblast growth factor enhances the benefits of cardiomyocyte transplantation. J Thorac Cardiovasc Surg 2002;124:50–6.
references.citation: Tomizawa Y, Komori M, Takada K, et al. Speed of angiogenesis: conditions to accelerate vessel formation in wound healing [in Japanese]. J Jpn Coron Assoc 2002;8:38–40.
references.citation: Clark ER. Observation on living growing lymphatics in the tail of the frog larva. Anat Rec 1909;3:183–98.
references.citation: Folkman J, Szabo S, Stovroff M, et al. Duodenal ulcer: discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann Surg 1991;214:414–25.
references.citation: Jain RK, Schlenger K, Hockel M, et al. Quantitative angiogenesis assays: progress and problems. Nat Med 1997;3:1203–8.
references.citation: Villaschi S, Nicosia RF. Angiogenic role of endogenous basic fibroblast growth factor released by rat aorta after injury. Am J Pathol 1993;143:181–90.
references.citation: Konturek SJ, Brzozowski T, Majka I, et al. Omentum and basic fibroblast growth factor in healing of chronic gastric ulcerations in rats. Dig Dis Sci 1994;39:1064–71.
references.citation: Baffour R, Berman J, Garb JL, et al. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast factor. J Vasc Surg 1992;16:181–91.